Lmr Partners LLP Cerevel Therapeutics Holdings, Inc. Transaction History

Lmr Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $8.07 Million - $8.85 Million	207,063 Added 22.36%	1,133,181 $46.3 Million
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $24.6 Million - $26 Million	601,535 Added 185.33%	926,118 $39.1 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $6.58 Million - $13.8 Million	324,583 New	324,583 $13.8 Million
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $1.46 Million - $2.23 Million	-50,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $1.06 Million - $1.94 Million	50,000 New	50,000 $1.48 Million
Q2 2021 Aug 16, 2021	SELL	$12.56 - $29.69 $278,141 - $657,485	-22,145 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $273,933 - $392,852	22,145 New	22,145 $304,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.